Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.
about
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitusInsulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitusEvaluating and treating cardiometabolic risk factors: a case discussionClinical implications of amylin and amylin deficiency.Upper gastrointestinal function and glycemic control in diabetes mellitus.Antiobesity pharmacotherapy in the management of type 2 diabetes.Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factorsThe importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.Gastric emptying in diabetes: clinical significance and treatment.Pramlintide for the treatment of diabetes mellitus.Postprandial dysmetabolism and cardiovascular disease in type 2 diabetesNew and emerging strategies for reducing cardiometabolic risk factors.Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus.Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk.Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes.The role of pramlintide for weight loss.Obesity and appetite controlNovel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.Amylin uncovered: a review on the polypeptide responsible for type II diabetes.Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus.Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1.Development of proteolytically stable N-methylated peptide inhibitors of aggregation of the amylin peptide implicated in type 2 diabetes.
P2860
Q24245173-CE8C5F51-612B-4E1E-9617-1B58B8DB98AEQ24246084-B19A47FD-C0B2-4837-BC8A-429C860FBE6FQ28196750-D97BB1BA-FC16-43A7-800C-74502241CCC7Q33757375-9B295D69-0542-4836-AA0B-C3331E088482Q33869207-D6BD400F-3CE8-43E5-AF28-AFA713CD05E5Q33883725-AE919648-286A-44B1-B163-EB8030D61B0CQ34133889-B7BF75BA-A96B-419B-A36D-1B85B7AA4B09Q34292419-6D120E71-9A73-4EE9-8D1A-88AF6C51023DQ34579697-9B6075CD-8665-456E-9E57-722F690A9194Q35169449-919F98BE-B582-4F28-9999-15CB571146E2Q35521022-0975FEF0-BFE1-429F-BF42-F6E791564879Q36459419-A0352B62-1AA6-4243-849E-931A0A49A9BFQ36593147-12AF5ED0-1270-4644-9B72-6F3310C744F6Q36634230-01FD2DFB-A031-4371-9439-7B8442842F91Q37193917-12F4042E-72EC-4F71-A5FF-18E21EA5F6B1Q37385620-6FBA7A9F-D1DA-4AB6-ACB4-AEB5070AB814Q37694145-64927544-D458-4593-AA66-975392776A47Q38035293-55966AC9-6853-452C-AA43-CFF4A18AF327Q38085727-3319316E-5070-464D-9D57-E7B5EA570D3EQ39846208-CE3212DB-D18E-4CE0-82E6-3724704BE86EQ43970895-53B65813-53AA-429C-A7CB-B7E1B0CD5DD8Q44122845-04F04C40-17E0-41CC-91F7-8B9D6695422EQ48286557-8F3371CA-2E72-4661-A38A-18A0DB8D7F94
P2860
Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Pramlintide, a synthetic analo ...... tide in Type 2 Diabetes Group.
@en
Pramlintide, a synthetic analo ...... tide in Type 2 Diabetes Group.
@nl
type
label
Pramlintide, a synthetic analo ...... tide in Type 2 Diabetes Group.
@en
Pramlintide, a synthetic analo ...... tide in Type 2 Diabetes Group.
@nl
prefLabel
Pramlintide, a synthetic analo ...... tide in Type 2 Diabetes Group.
@en
Pramlintide, a synthetic analo ...... tide in Type 2 Diabetes Group.
@nl
P2093
P921
P356
P1433
P1476
Pramlintide, a synthetic analo ...... tide in Type 2 Diabetes Group.
@en
P2093
O G Kolterman
R G Thompson
S L Schoenfeld
P304
P356
10.2337/DIACARE.21.6.987
P407
P577
1998-06-01T00:00:00Z